An approach for conjugation of 177Lu- DOTA-SCN- Rituximab (Biosim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins Lymphoma patients

Indian Journal of Medical Research

Volumn 139, Issue APR, 2014, Pages 544-554

  Thakral, Parul ^a   Singla, Suhas ^a   Yadav, Madhav Prasad ^a   Vasisht, Atul ^a   Sharma, Atul ^a   Gupta, Santosh Kumar ^a   Bal, C S ^a   Snehlata, ^a   Malhotra, Arun ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cd20; Lutetium 177; Mab; NHL; Radioimmunotherapy; Rituximab (Biosim)

Indexed keywords

4 ISOTHIOCYANATE BENZYL 1,4,7,10 TETRAAZACYCLODODECANE; CHELATING AGENT; RITUXIMAB; RITUXIMAB LU 177; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; LUTETIUM; MONOCLONAL ANTIBODY; RADIOISOTOPE;

ARTICLE; B CELL LYMPHOMA; CANCER RECURRENCE; CASE REPORT; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG RESPONSE; DRUG STABILITY; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; ISOTOPE LABELING; LEUKOCYTE COUNT; NONHODGKIN LYMPHOMA; PH; RADIOASSAY; RADIOIMMUNOTHERAPY; SINGLE DRUG DOSE; THIN LAYER CHROMATOGRAPHY; THROMBOCYTE COUNT; CHEMISTRY; INDIA; LYMPHOMA, B-CELL; PROCEDURES;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; HUMANS; IMMUNOCONJUGATES; INDIA; LUTETIUM; LYMPHOMA, B-CELL; RADIOIMMUNOTHERAPY; RADIOISOTOPES;

EID: 84902182939     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. 90Y-Ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005; 16: 786-92.
2. 99mTc using the tricarbonyl technology. Nucl Med Biol 2011; 38: 19-28.
3. 131I-tositumomab in clinical practice. J Nucl Med 2007; 48: 1767-76.
4. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med 2009; 50: 8-17.
5. 90Y labelled anti-CD20 monoclonal antibody. Clin Cancer Res 1999; 5 (Suppl 10): 3281s- 6s.
6. Bernhardt P, Benjegard SA, Kolby L, Johanson V, Nilsson O, Ahlman, H, et al. Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. Int J Radiat Oncol Biol Phys 2001; 51: 514-24.
7. Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol 2001; 40: 602-8.
8. 111In-cG250 imaging. J Nucl Med 2012; 53: 82-9.
9. 177lutetium-labelled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23: 4591-601.
10. 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. Eur J Nucl Med Mol Imaging 2009; 36: 1443-52.
11. Audicio PF, Castellano G, Tassano MR, Rezzano ME, Fernandez M, Riva E, et al. [177Lu]DOTA-anti-CD20: labeling and pre-clinical studies. Appl Radiat Isot 2011; 69: 924-8.
12. 99mTc- rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent. Eur J Nucl Med Mol Imaging 2006; 33: 53-9.
13. Torres-Garcia E, Ferro-Flores G, Arteaga de Murphy C, Correa-Gonzalez L, Pichardo-Romero PA. Biokinetics and dosimetry of 188Re-anti-CD20 in patients with non-Hodgkin's lymphoma: preliminary experience. Arch Med Res 2008; 39: 100-9.
14. Jalilian AR, Mirsadeghi L, Yari-kamrani Y, Rowshanfarzad P, Kamali-dehghan M, Sabet M. Development of [64Cu]-DOTA-anti-CD20 for targeted therapy. Radioanal Nucl Chem 2007; 274: 563-8.
15. 153Sm-DTPA-rituximab for radioimmunotherapy. Nukleonika 2009; 54: 271-7.
16. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72: 77-89.
17. The United States Pharmacopeia Supplement 4a 1984.
18. Press OW, Eary JF, Badger CC, Martin PJ, Applebaum FR, Levy R, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989; 7: 1027-38.
19. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-l31-labeled LL2 monoclonal antibody. J Clin Oncol 1991; 9: 548-64.
20. Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labelled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992; 10: 1696-711.
21. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219-24.
22. Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Dunn R, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti- CD22 monoclonal antibody. Cancer Res 1995; 55 (Suppl 23): 5899s-907s.
23. Emmanouilides C. Current status of radioimmunotherapy for non-Hodgkin lymphoma. Haema 2003; 6: 314-27.
24. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, et al. Radioimmunotherapy of B-cell lymphoma with (131I)anti-B1 (anti-CD20) antibody. NEngl J Med 1993; 329: 459-65.
25. Johnson PW, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer 2001; 85: 1619-23.
26. Avivi I, Robinson S, Goldstone A. Clinical use of rituximab in hematological malignancies. Br J Cancer 2003; 89: 1389-94.
27. Roy P S, Sengar M, Menon H, Bagal B, Khattry N, Shridhar E et al. A retrospective single centre analysis of safety, toxicity and efficacy of rituximab (original) and its biosimilar in diffuse large B-cell lymphoma patients treated with chemo- immunotherapy (Abstract). Ann Oncol 2012; 23 (Suppl 9): p. 1074.
28. Kameswaran M, Pandey U, Samuel G, Sarma HD, Venkatesh M. Therapy. THER 02 (ORAL): Preparation and evaluation of 90Y rituximab for its potential as a radioimmunotherapeutic agent for non Hodgkin's lymphoma. Indian J Nucl Med 2010; 25: 117-20.